Back to Search
Start Over
[Infliximab in moderate to severe steroid-dependent or steroid-refractory ulcerative colitis].
[Infliximab in moderate to severe steroid-dependent or steroid-refractory ulcerative colitis].
- Source :
-
Recenti progressi in medicina [Recenti Prog Med] 2007 Nov; Vol. 98 (11), pp. 560-4. - Publication Year :
- 2007
-
Abstract
- Tumor Necrosis Factor alpha plays a main role in ulcerative colitis. Thirteen male and 8 female affected by moderate to severe steroid-dependent or refractory-severe ulcerative colitis were treated with 5 mg/kg of infliximab (Remicade). At 12 week efficacy, steroid-sparing, colectomy and side effects were evaluated. In steroid-dependent group (13 patients): 8 patients had a clinical benefit (7 obtained a clinical remission, 54%), 8 (61.5%) discontinued steroids, 1 patient underwent surgery. In steroid-severe refractory group (8 patients): 3 patients (37.5%) had a clinical remission, 2 (25%) had a clinical response and 3 (37.5%) underwent colectomy. One mild infusion reaction and one adverse event (itch) were observed. Infliximab is an effective and safe therapy in patients with moderate to severe steroid dependent and refractory ulcerative colitis.
- Subjects :
- Adult
Drug Resistance
Drug Therapy, Combination
Female
Follow-Up Studies
Humans
Infliximab
Male
Middle Aged
Retrospective Studies
Severity of Illness Index
Treatment Outcome
Adrenal Cortex Hormones therapeutic use
Anti-Inflammatory Agents therapeutic use
Antibodies, Monoclonal therapeutic use
Colitis, Ulcerative drug therapy
Gastrointestinal Agents therapeutic use
Subjects
Details
- Language :
- Italian
- ISSN :
- 0034-1193
- Volume :
- 98
- Issue :
- 11
- Database :
- MEDLINE
- Journal :
- Recenti progressi in medicina
- Publication Type :
- Academic Journal
- Accession number :
- 18044405